Mind Medicine Closes The Year Out With Further Management Departures
Mind Medicine (NEO: MMED) has seen further management departures, following the departure of its CEO this past summer. Classified as
Read more
Psychedelics
Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study
Mind Medicine (NEO: MMED) this morning indicated that things are not going quite to plan with an IND submission for
Read more
KetamineOne Reports Fiscal Q1 2022 Financials: $2.0 Million In Revenue
KetamineOne Capital (NEO: MEDI) released this morning its financial reports for the fiscal quarter ended October 31, 2021. The firm managed
Read more
Bright Minds Bioscience: A Deep Dive
Today we are diving into a firm focused on mental health, whom is also a recently Nasdaq-listed Psychedelic Stock, Bright
Read more
PharmaTher Secures Japanese Patent For Ketabet
PharmaTher Holdings (CSE: PHRM) announced today that it has been granted a Japanese patent for its ketamine combination formulation, Ketabet. The
Read more
Numinus Wellness Parts With Chief Strategy Officer, Issues 2.0 Million Shares With Separation
Numinus Wellness Inc. (TSXV: NUMI) announced on Thursday that its Chief Strategy Officer Stacey Wallin is leaving the company. The
Read more
Numinus Wellness Announces Move To Toronto Stock Exchange
Numinus Wellness (TSV: NUMI) is set to be one of the next firms listed on the Toronto Stock Exchange. The
Read more
Compass Pathways Granted Its Tenth Overall Patent Related To Psilocybin
Compass Pathways (NASDAQ: CMPS) this morning issued a brief release, indicating it has been granted a fifth patent in the
Read more
Compass: Canaccord Reiterates $80 Price Target After Study Data
Earlier this month, Compass Pathways (Nasdaq: CMPS) announced positive topline results and its key findings in its Phase 2b clinical
Read more
Revive Therapeutics Announces Research Collaboration Agreement For Psilocybin Microneedle Patch
Revive Therapeutics (CSE: RVV) announced today that it has entered into a research collaboration agreement with PharmaTher Holdings Ltd. (CSE: PHRM).
Read more